Carbamates of 2-heterocyclic-1,2-ethanediols
Carbamate compounds of 2-heteroaryl-1,2-ethanediol are described. The compounds are effective in the treatment of disorders of the central nervous system, especially as anti-convulsive or anti-epileptic agents.
1 . A compound represented by the formula:
wherein A is a heterocyclic moiety selected from the group consisting of
wherein each of R 3 , R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, trihalomethyl, alkyl and aryl, and X is selected from sulfur, oxygen and nitrogen; B 1 and B 2 are independently hydroxy or OCONR 1 , R 2 , provided that B 1 and B 2 are not simultaneously hydroxy; and R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylaryl, arylalkyl, aryl and aryloxy, and their enantiomers, enantiomeric mixtures thereof, and pharmaceutically acceptable salts thereof.
2 . A compound in accordance with claim 1 , wherein said compound is a pure enantiomer or an enantiomeric mixture wherein one enantiomer predominates.
3 . A compound in accordance with claim 1 , wherein B 1 and B 2 are OCONH 2 .
4 . A compound in accordance with claim 1 , wherein only one of B 1 and B 2 is OCONH 2 .
5 . Cancelled
6 . A compound in accordance with claim 1 , wherein A is selected from the group consisting of:
wherein each of R 3 , R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, trihalomethyl, alkyl and aryl, and X is selected from sulfur, oxygen and nitrogen.
7 - 12 . Cancelled.
13 . A pharmaceutical composition comprising an effective amount of a compound of in accordance with claim 1 for treating disorders of the central nervous system.
14 . A pharmaceutical composition in accordance with claim 13 , wherein the central nervous systems disorder being treated is selected from the group consisting of convulsions, epilepsy, stroke, neurogenic pain and muscle spasm.
15 . A pharmaceutical composition in accordance with claim 13 , wherein said compound is a pure enantiomer or an enantiomeric mixture wherein one enantiomer predominates.
16 . A method for the treatment of a central nervous system disorder which comprises administering to a host requiring such treatment an effective amount of a compound in accordance with claim 1 .
17 . A method in accordance with claim 16 , wherein said compound is a pure enantiomer or an enantiomeric mixture wherein one enantiomer predominates.